USC/Norris Comprehensive Cancer Center

Clinical research site in Los Angeles, California · 1200 N STATE ST, LOS ANGELES, CA 90033-1029 · (323) 409-1313

Part of USC Norris / Keck Medicine

As of July 2026, 167 paid clinical trials are recruiting at USC/Norris Comprehensive Cancer Center in Los Angeles, California. Active studies at this site cover conditions such as Malignant Solid Neoplasm, Breast Carcinoma and Anatomic Stage III Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at USC/Norris Comprehensive Cancer Center (167)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

28 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

28 locations incl. Little Rock

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07258511·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

for Carcinoma, Hepatocellular

29 locations incl. Los Angeles

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227012·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostatic Neoplasms, Castration-Resistant

49 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07225946·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

for Untreated, Unresectable, or Metastatic Colorectal Cancer

48 locations incl. Tucson

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for Colorectal Neoplasms

104 locations incl. Glendale

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05253651·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

54 locations incl. Daphne

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

48 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

for Metastatic Non-small Cell Lung Cancer With MTAP Deletion

39 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07063745·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for Breast Neoplasms

38 locations incl. Hot Springs

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06926868·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

for Advanced Melanoma

44 locations incl. Gilbert

Sponsor: Replimune, Inc.

Sex: All·Age: 12+

Code: NCT06264180·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

58 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

for Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

27 locations incl. Los Angeles

Sponsor: Bayer

Sex: All·Age: All ages

Code: NCT04142437·Recruiting·Listed Oct 2019

Apply to this trial

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

for Alzheimer Disease

49 locations incl. Gilbert

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Sex: All·Age: 55 - 90

Code: NCT06585787·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

for Endometrial Adenocarcinoma

42 locations incl. Phoenix

Sponsor: Acrivon Therapeutics

Sex: Female·Age: 18+

Code: NCT05548296·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for Advanced Solid Tumor

31 locations incl. La Jolla

Sponsor: PMV Pharmaceuticals, Inc

Sex: All·Age: 12+

Code: NCT04585750·Phase 1, Phase 2·Recruiting·Listed Oct 2020

Apply to this trial

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

28 locations incl. Homewood

Sponsor: Sanofi

Sex: All·Age: 18+

Code: NCT06290128·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

for Psychosis Associated With Alzheimer's Disease

86 locations incl. Gilbert

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Sex: All·Age: 55 - 90

Code: NCT05980949·Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

for Head and Neck Squamous Cell Carcinoma

29 locations incl. Duarte

Sponsor: Tempus AI

Sex: All·Age: 18+

Code: NCT06163534·Recruiting·Listed Dec 2023

Apply to this trial

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for HER2 Mutation-Related Tumors

29 locations incl. La Jolla

Sponsor: Iambic Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06253871·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for Relapsed Non-Hodgkin Lymphoma

32 locations incl. Irvine

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05826535·Phase 1, Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

for Adenocarcinoma, Pancreatic Ductal

30 locations incl. Los Angeles

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT05968326·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

Neoadjuvant Darovasertib in Primary Uveal Melanoma

for Uveal Melanoma

35 locations incl. Scottsdale

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07015190·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for Advanced Cancer

37 locations incl. Birmingham

Sponsor: Artios Pharma Ltd

Sex: All·Age: 18+

Code: NCT04657068·Phase 1, Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for AML

36 locations incl. Gilbert

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06001788·Phase 1·Recruiting·Listed Aug 2023

Apply to this trial

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

for cGVHD

31 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05919511·Recruiting·Listed Jun 2023

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

for Chronic Graft-versus-host-disease

13 locations incl. Birmingham

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 2+

Code: NCT04710576·Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

for Superficial Bladder Cancer

48 locations incl. Birmingham

Sponsor: enGene, Inc.

Sex: All·Age: 18+

Code: NCT04752722·Phase 1, Phase 2·Recruiting·Listed Feb 2021

Apply to this trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

for Prostate Cancer

30 locations incl. Birmingham

Sponsor: Janux Therapeutics

Sex: Male·Age: 18 - 100

Code: NCT05519449·Phase 1·Recruiting·Listed Aug 2022

Apply to this trial

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

for Myeloproliferative Neoplasms

22 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07441694·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

for GIST - Gastrointestinal Stromal Tumor

16 locations incl. Los Angeles

Sponsor: Kumquat Biosciences Inc.

Sex: All·Age: 18+

Code: NCT07406633·Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

for Non-Muscle Invasive Bladder Neoplasms

13 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07309445·Recruiting·Listed Dec 2025

Apply to this trial

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

for Lymphoma, Non-Hodgkin's

21 locations incl. Scottsdale

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07226843·Phase 1·Recruiting·Listed Nov 2025

Apply to this trial

Showing the 40 most relevant of 167 recruiting trials at this site. Browse all with filters →

More research sites in Los Angeles

Cedars-Sinai Medical Center (227 trials)
Children's Hospital Los Angeles (133 trials)
University of California, Los Angeles (110 trials)
University of Southern California (93 trials)
Cedars Sinai Medical Center (68 trials)
UCLA / Jonsson Comprehensive Cancer Center (67 trials)
University of California Los Angeles (65 trials)
USC / Norris Comprehensive Cancer Center (64 trials)
UCLA (53 trials)
USC Norris Comprehensive Cancer Center (53 trials)

Explore more

Paid clinical trials in Los Angeles, CA · California clinical trials